Clinical Trial Update: A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer [Phase 3]

View source ↗

Summary

A Phase III randomized trial evaluating Dato-DXd in combination with Durvalumab for neoadjuvant/adjuvant treatment in triple-negative or hormone receptor-low/HE…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Dato-DXd (datopotamab deruxtecan)
• IMFINZI (DURVALUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING